Merck & Company Inc (MRK)vscbdMD Inc (YCBD)
MRK
Merck & Company Inc
$141.16
-0.63%
HEALTHCARE · Cap: $360.08B
YCBD
cbdMD Inc
$0.37
+0.27%
HEALTHCARE · Cap: $4.06M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 317933% more annual revenue ($66.57B vs $20.93M). MRK leads profitability with a 4.8% profit margin vs -13.8%. YCBD trades at a lower P/E of 1.6x. YCBD earns a higher WallStSmart Score of 39/100 (F).
MRK
Hold36
out of 100
Grade: F
YCBD
Hold39
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.7%
Fair Value
$83.64
Current Price
$141.16
$57.52 premium
Margin of Safety
+4.6%
Fair Value
$0.79
Current Price
$0.37
$0.42 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Attractively priced relative to earnings
Reasonable price relative to book value
Conservative balance sheet, low leverage
Revenue surging 20.6% year-over-year
Areas to Watch
Trading at 8.3x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -28.6% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bull Case : YCBD
The strongest argument for YCBD centers on P/E Ratio, Price/Book, Debt/Equity. Revenue growth of 20.6% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 115.8x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Bear Case : YCBD
The primary concerns for YCBD are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
MRK profiles as a value stock while YCBD is a growth play — different risk/reward profiles.
YCBD carries more volatility with a beta of 2.25 — expect wider price swings.
YCBD is growing revenue faster at 20.6% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
YCBD scores higher overall (39/100 vs 36/100) and 20.6% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →cbdMD Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
cbdMD, Inc. produces and distributes various cannabidiol (CBD) products. The company is headquartered in Charlotte, North Carolina.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?